An experimental weight-loss drug from Eli Lilly & Co. helped patients lose weight with few side effects, according to the ...

Sarah Strauss. Bob Jones University — Oronoco: Abigail Graham. Cedarville University —: Johanna Trondson. Central Lakes College —: Johnny Tong. Concordia University —: Hope Nelson; Winona: Naa Kordai ...

Eli Lilly's (LLY) experimental obesity drug, eloralintide, shows up to 11% weight loss in 12 weeks with minimal side effects in early-stage trial. Read more here.

In this video, Erica L. Mayer, MD, MPH, director of breast cancer clinical research at Dana-Farber Cancer Institute, discusses results of the TRADE study, which she presented at ASCO Annual ...

The two products accounted for about 48% of Eli Lilly's most recent quarterly sales and drove most of the top-line growth.

Eli Lilly's experimental obesity drug, eloralintide, helped some patients lose 11.5% of their body weight at 12 weeks in an ...

The Zacks Research Daily presents the best research output of our analyst team. Today’s Research Daily features new research reports on 16 major stocks, including Eli Lilly and Co. (LLY), The Home ...

Millions of Americans use GLP-1s, and many have relied on versions produced by compounding pharmacies because of the high monthly costs for brand names like Mounjaro and Zepbound.

Korean officials discovered the painting in the Smart Museum’s collection at the University of Chicago. It was stolen from a ...

Eli Lilly & Co. and health tech company Kalderos Inc. are seeking to revive lawsuits in the DC Circuit after a federal judge ...

Eli Lilly continues to dominate the obesity market with Zepbound and Orforglipron, leading JPMorgan to see it as a top pick ...